Very good news but the selling continues...
Vaso Corporation Announces Extension of Exclusive Sales Representation Agreement with GE Healthcare Through 2022
PLAINVIEW, NY / ACCESSWIRE / December 4, 2017 / Vaso Corporation (OTC PINK: VASO) (formerly Vasomedical, Inc.) today announces the amendment of the sales representation agreement between its subsidiary, Vaso Diagnostics, Inc. d/b/a VasoHealthcare, and GE Healthcare ("GEHC"), the healthcare business unit of General Electric Company (GE), originally signed on May 19, 2010.
The amendment extends the term of the original agreement, which began on July 1, 2010 and was previously extended in 2012 and 2015, through December 31, 2022, subject to earlier termination under certain circumstances, making it the longest extension thus far with a remaining term of five years from the end of this year. Under the agreement, VasoHealthcare is the exclusive representative for the sale of select GE Healthcare diagnostic imaging products to specific market segments/accounts in the 48 contiguous states of the United States and the District of Columbia.
"Vaso has become an integral part of GE Healthcare's U.S. diagnostic imaging strategy," said Lee Cooper, President and CEO of GE Healthcare. "We look forward to our continued collaboration. It's an exciting time for the healthcare industry."
"This third extension of the representation agreement is a testament of the tremendous success and significant growth we have had with GEHC in the diagnostic imaging market in the last seven and a half years, thanks to the professionalism, dedication and performance of our VasoHealthcare leadership and sales team," commented Jun Ma, President and CEO of Vaso Corporation. "Along with our ongoing collaboration with GEHC Digital under a separate agreement for the sale, implementation, and service of its imaging IT products, this extension of our representation agreement for diagnostic imaging equipment further strengthens our long-lasting cooperative relationship with GEHC."
